Her-2/neu and breast cancer Journal Article


Authors: Kaptain, S.; Tan, L. K.; Chen, B.
Article Title: Her-2/neu and breast cancer
Abstract: Breast cancer is the most common malignancy in women in the United States in the year 2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer. Herceptin, a "humanized" murine monoclonal antibody directed against the extracellular domain of the Her-2/neu protein, is being used to treat breast cancer that overexpresses Her-2/neu. The status of Her-2/neu in the tumor has become a critical factor in the management strategy of a breast cancer patient. The objective of this article is to provide a comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing of Her-2/neu.
Keywords: immunohistochemistry; clinical trial; review; cisplatin; doxorubicin; antineoplastic agents; paclitaxel; antineoplastic agent; protein domain; adenocarcinoma; gene overexpression; proto oncogene; breast cancer; gene amplification; cyclophosphamide; breast neoplasms; monoclonal antibody; in situ hybridization; antibodies, monoclonal; fluorescence in situ hybridization; breast carcinoma; tamoxifen; receptor, erbb-2; taxane derivative; trastuzumab; anthracycline; hormone resistance; oncogene neu; her-2/neu; herceptin; humans; prognosis; human; female; priority journal; oncogene c erb; c-erb-b2
Journal Title: Diagnostic Molecular Pathology
Volume: 10
Issue: 3
ISSN: 1052-9551
Publisher: Lippincott Williams & Wilkins  
Date Published: 2001-09-01
Start Page: 139
End Page: 152
Language: English
DOI: 10.1097/00019606-200109000-00001
PUBMED: 11552716
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lee K Tan
    147 Tan
  2. Beiyun Chen
    49 Chen